IL1B and COVID-19: Because of the heterogeneity of the underlying immune–inflammatory mechanisms that pave the way to the manifestation of COVID-19 and because of the need of identifying biological targets for potential interventions, we evaluated postmortem lung specimens (i.e., the site of SARS-CoV-2 infection) of severe COVID-19 patients and controls for the expression of immune-inflammatory biomarkers, including IL-1β, IL-6, IFN-β, and IFN- λ.